We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Lazard Inc | NYSE:LAZ | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
1.01 | 2.64% | 39.23 | 39.37 | 38.3901 | 38.42 | 212,723 | 20:03:09 |
- Most healthcare industry leaders expect the pandemic to continue through 2022 and beyond -
Lazard Ltd (NYSE: LAZ) today released its fourth annual in-depth study of strategic challenges and opportunities in the global healthcare industry, surveying 200 C-level executives and investors across three global sectors: Biopharmaceuticals; Medical Devices and Diagnostics; and Healthcare Services. As the COVID-19 pandemic continues to evolve, this year’s study focuses on the healthcare leaders’ pandemic-related challenges and expectations, as well as the strategic priorities for their businesses.
In last year’s study, there was a high correlation between healthcare industry leaders’ responses and the subsequent course of events. This year’s study finds that most healthcare leaders expect a protracted battle with the global health crisis, with the majority of respondents expecting the pandemic to continue through 2022 and beyond. They also have significant concerns about scenarios that could create risk for resurgence, such as vaccine hesitancy, distribution shortfalls in developing countries, and new variants. In addition, the majority of respondents expect the pandemic to have lasting impacts, both positive and negative, on their industry, the business world and socioeconomic trends globally.
“Most healthcare industry leaders expect the pandemic to permanently accelerate the digital revolution, technology and automation, but a significant number also expect worsening national and global inequity, worsening political divides and protectionist trends,” said David Gluckman, Global Head of Lazard’s Healthcare Group. “In a challenging environment for the healthcare industry, scientific innovation and advances in digital technologies are seen as the greatest forces for positive transformation.”
“The need for growth and innovation continues to drive companies toward strategic transactions, including M&A, alliances and licensing activity,” said Stephen Sands, Chairman of Lazard’s Global Healthcare Group. “The majority of respondents predict increased strategic activity for the remainder of this year and into 2022 and beyond.”
The study offers a variety of insights, including the following selected highlights:
The Global Healthcare Leaders Study surveyed 171 C-level executives and 29 investors across three sectors: Biopharmaceuticals; Medical Devices and Diagnostics; and Healthcare Services. These 200 healthcare leaders represent many of the largest healthcare entities globally, smaller public and private companies, and prominent investment firms.
The Global Healthcare Leaders Study reflects Lazard’s approach to long-term thought leadership, commitment to the sectors in which it participates, and focus on intellectual differentiation. An executive summary of the Study is posted at www.lazard.com/perspective.
Lazard’s Global Healthcare Group advises senior executives and boards of directors on strategic M&A, corporate preparedness, capital advisory, and other strategic and financial matters. The group is active in all areas of the healthcare and life sciences industry, including pharmaceuticals, biotechnology, healthcare services, and medical devices.
ABOUT LAZARD
Lazard, one of the world's preeminent financial advisory and asset management firms, operates from 41 cities across 26 countries in North America, Europe, Asia, Australia, Central and South America. With origins dating to 1848, the firm provides advice on mergers and acquisitions, strategic matters, restructuring and capital structure, capital raising and corporate finance, as well as asset management services to corporations, partnerships, institutions, governments and individuals. For more information on Lazard, please visit www.lazard.com. Follow Lazard at @Lazard.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210927005221/en/
Media: Judi Mackey judi.mackey@lazard.com +1 212 632 1428
Poppy Trowbridge poppy.trowbridge@lazard.com +44 20 7187 2065
Clare Pickett (US) clare.pickett@lazard.com +1 212 632 6963
1 Year Lazard Chart |
1 Month Lazard Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions